Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASCERTAIN: Everolimus with calcineurin inhibitor reduction in maintenance renal transplant recipients
2004-002267-24Phase 3Completed
- Sponsor
- Novartis
- Start
- Oct 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of everolimus in kidney transplant (3 arms), sponsored by Novartis. Primary endpoint: Measured glomerular filtration rate at 24 months. Started Oct 2004; status: completed.
02
Drugs
everolimus
03
Conditions
kidney transplant
Beyond the preview
Go deeper on 2004-002267-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002267-24.